KIN Health
KIN Health describes clinician-reviewed treatment and ongoing refill support across several compounded products. Its named GLP-1 pharmacies include Boothwyn, which received an FDA human-drug warning in 2026.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The public intake and refill model is described more clearly than the identity of the treating practice. Before proceeding, resolve the pharmacy assignment and ask about the documented Boothwyn quality findings. A listed partner does not prove that a particular prescription came from an affected lot.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Lowest listed: Semaglutide injection, from $169/mo
Visit KIN Health →KIN Medical, Inc. operates KIN Health, an online service advertising clinician-reviewed compounded medication. Its catalog includes semaglutide, tirzepatide, sermorelin, NAD+ and PT-141. NAD+ is a coenzyme rather than a peptide. Product pages distinguish multiple routes and give some concentrations or tablet strengths. Those details help identify the proposed preparation, but do not establish that different routes produce equivalent outcomes. The patient still needs an appropriate prescription and an identified dispenser.
What KIN Health prescribes, by goal
Weight
- SemaglutideFDA-approved
- Injection (compounded)From $169/mo
- TirzepatideFDA-approved
- Injection (compounded)From $199/mo
The GLP-1 page describes weekly semaglutide and tirzepatide injections with provider support. Outcomes from branded-drug trials do not establish results for KIN’s compounded preparations or its service. Confirm ingredients, dose, concentration and the dispensing pharmacy.
Sexual health
- PT-141 (bremelanotide)FDA-approved
Listed by the seller; no price we hold.
PT-141 appears in multidose injection and nasal products as well as dissolving tablets. These compounded products should not be confused with the FDA-approved Vyleesi autoinjector. A shared ingredient does not transfer its approved formulation, labeling or clinical evidence.
Longevity
- NAD+Compounding conditions apply
Listed by the seller; no price we hold.
NAD+ is offered through injection, nasal and sublingual routes. Its role in cellular metabolism does not establish that a compounded preparation reverses aging or improves symptoms. Ask which measurable concern would justify treatment.
Recovery
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
Sleep
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
Sermorelin appears as an injection, nasal spray and dissolving tablet. The page describes patient-reported timelines for sleep and recovery. Such timelines do not establish comparative efficacy across these routes or a predictable result for a new patient.
Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.
Who prescribes
A licensed clinician
The website does not name the assigned prescriber or medical practice. The pages describe providers licensed in the patient’s state, without identifying an assigned clinician or medical practice publicly. The GLP-1 page names Drug Crafters and Boothwyn as pharmacy partners. That does not assign either pharmacy to a specific patient or establish that it fulfills every KIN product. Ask for the clinical practice, prescriber and dispensing address before payment. Pharmacy accreditation is presented as a seller claim. It does not replace consideration of FDA inspection and enforcement records.
The sermorelin, NAD+ and PT-141 pathways begin with a health questionnaire followed by a licensed provider’s review. The pages say no appointment is required to start. A mandatory video or phone visit is not mentioned. Prescribing remains the clinician’s decision; buying a product does not guarantee approval. Follow-up includes ongoing provider support and review at each refill, with dose changes when appropriate. That is not a published fixed schedule of live consultations. Ask how to obtain a live visit and how urgent adverse effects are handled. The pages advertise a full refund when a provider does not approve treatment.
Are labs required?
Not mentioned
The GLP-1 page includes review of laboratory results if needed. That is different from providing a new laboratory test at no charge. The other product pages do not establish a universal test panel or monitoring schedule. Ask which baseline results are required for the chosen medication and what repeat testing is planned. Any extra test charge should be confirmed separately.
Ready to start with KIN Health?
Lowest listed price: Semaglutide injection, from $169/mo. Confirm it on the seller’s own site.
What it claims, and what it cites
KIN advertises improved recovery, body composition, sleep and energy, with several timelines described as patient-reported. Those statements do not substitute for evidence on the exact preparation and route. Its GLP-1 pharmacy disclosure also warrants a direct question. FDA’s January 2026 warning to Boothwyn describes human sterile-drug deficiencies and specified semaglutide and tirzepatide quality failures. It acknowledges a 2025 recall and requested further corrective action. The letter does not identify a KIN patient or establish the quality of a current KIN prescription. Drug Crafters separately received a historical 2019 state-referral letter concerning sterile practice. Ask who dispenses your prescription and what current evidence addresses relevant quality findings.
How it bills
The GLP-1 page separates a starting-month offer from subsequent monthly prices. Its refill statements differ from the other product pages. GLP-1 material says each refill is approved by the buyer without auto-renewal. Sermorelin, NAD+ and PT-141 pages advertise one-time or automatic refills. Confirm the actual product’s renewal choice and stopping process. Thirty-day supplies are not automatically calendar-month billing. The public terms were not readable through the available text reader, leaving the complete contract unresolved.
For and against
- For: Provider review precedes dispensing
- For: Ongoing refill support described
- For: GLP-1 pharmacy partners named
- For: Routes and some strengths disclosed
- Against: Assigned medical practice not identified
- Against: Boothwyn human-drug warning needs discussion
- Against: Refill terms vary by product
- Against: Complete contract terms need confirmation
The evidence behind what it sells
- Semaglutide Side Effects: What the Wegovy Trials and Label Recorded
- Bremelanotide Side Effects: Nausea, Blood Pressure and Skin Darkening
- NAD Side Effects: What Injection, IV and Oral Precursor Studies Reported
- Sermorelin Side Effects: What the Trials and FDA Record Report
- Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded
- Bremelanotide (PT-141): The FDA Approval and What the Trials Showed
Right for
Someone prepared to verify the prescriber, dispenser and product-specific refill agreement before deciding whether to proceed.
Look elsewhere if
Someone who needs independently verified pharmacy quality, proven results across every offered route, or guaranteed live follow-up.
Other sellers for weight
Maves
Also prescribes Semaglutide, Tirzepatide.
Nucore Health
Also prescribes Semaglutide, Tirzepatide.
Premium Health
Also prescribes Semaglutide, Tirzepatide.
KIN Health
Frequently asked questions
- Does KIN identify its pharmacy partners?
- The GLP-1 page names Drug Crafters and Boothwyn. It does not establish which will fill an individual prescription or whether those names apply to every product.
- Does the Boothwyn warning prove a KIN prescription was affected?
- No. The FDA letter concerns specified facility practices and products. It does not identify a KIN patient. The current dispensing pharmacy and relevant quality evidence still deserve confirmation.
- Are all KIN products available without automatic refills?
- The GLP-1 page advertises buyer-approved refills without auto-renewal. Other product pages mention one-time or automatic refills, so the actual order settings and agreement matter.
Sources
- KIN Medical, Inc. platform and fee statements
- Weight-loss prices, manual refill claims and named pharmacies
- Sermorelin forms and thirty-day supplies
- NAD+ routes and supply prices
- PT-141 quantities and prescription disclaimer
- FDA human-drug warning to Boothwyn Pharmacy, LLC
- FDA historical Drug Crafters state referral
- FDA explanation of compounded-drug approval and quality limits
See what KIN Health prescribes today
KIN Health sets its own prices, plans and the states it serves. Check them before you start.